"Phase II Prostate Cancer Vaccine Trial: Report of a Study Involving 37 Patients With Disease Recurrence Following Primary Treatment."

According to the authors' abstract of an article published in Prostate, "Background: A Phase II trial was conducted to assess the efficacy of infusions of dendritic cells (DC) and two HLA-A2-specific prostate-specific membrane antigen (PSMA) peptides (PSM-P1 and -P2). This report describes the evaluation of 37 subjects admitted with presumed local recurrence of prostate cancer after primary treatment failure. Methods: All subjects received six infusions of DC pulsed with PSM-P1 and -P2 at 6-week intervals. Clinical monitoring was conducted pre-, during, and post-Phase II study. Data included complete blood count, bone and total alkaline phosphatase, prostate markers,...

Want to see the full article?

• Purchase this article for only $3.00